Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
50 studies found for:    "Pancreatic islet cell tumors"
Show Display Options
Rank Status Study
1 Terminated
Has Results
A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors
Conditions: Carcinoma, Islet Cell;   Carcinoma, Pancreas
Interventions: Drug: sunitinib malate;   Drug: Placebo
2 Completed Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
Condition: Islet Cell Tumor
Interventions: Drug: Everolimus;   Drug: Pasireotide + Everolimus
3 Completed Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor
Interventions: Drug: capecitabine;   Drug: cisplatin;   Drug: streptozocin;   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: protein analysis;   Genetic: proteomic profiling;   Other: laboratory biomarker analysis
4 Completed
Has Results
RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma
Conditions: Neuroendocrine Carcinoma;   Islet Cell Carcinoma
Interventions: Drug: RAD001;   Drug: Octreotide Depot
5 Withdrawn Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Carcinoma
Interventions: Drug: octreotide acetate;   Drug: vatalanib;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: biological therapy;   Procedure: endocrine therapy;   Procedure: enzyme inhibitor therapy;   Procedure: growth factor antagonist therapy;   Procedure: hormone therapy;   Procedure: protein tyrosine kinase inhibitor therapy;   Procedure: somatostatin analogue therapy
6 Completed
Has Results
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
Conditions: Neuroendocrine Tumor;   Islet Cell Tumor
Interventions: Drug: Sunitinib malate;   Procedure: Hepatic Artery Embolizations
7 Completed PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor
Intervention: Drug: bortezomib
8 Recruiting Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
Conditions: Islet Cell Tumor;   Pancreatic Cancer;   Pancreatic Disease
Interventions: Other: medical chart review;   Other: survey administration;   Other: biospecimen collection
9 Unknown  Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Metastatic Cancer
Intervention: Drug: PVA microporous hydrospheres/doxorubicin hydrochloride
10 Completed
Has Results
AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: AMG 706;   Drug: octreotide
11 Completed Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Neoplastic Syndrome
Interventions: Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
12 Completed Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Neoplastic Syndrome
Intervention: Drug: thalidomide
13 Terminated Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors
Conditions: Head and Neck Cancer;   Islet Cell Tumor;   Metastatic Cancer;   Pheochromocytoma
Interventions: Drug: octreotide acetate;   Radiation: yttrium Y 90 resin microspheres
14 Completed A Study of IMC-A12 in Islet Cell Cancer
Conditions: Carcinoma;   Neuroendocrine Tumors
Interventions: Biological: IMC-A12 (cixutumumab);   Drug: depot octreotide
15 Completed
Has Results
Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy
Conditions: Islet Cell Carcinoma;   Neuroendocrine Carcinoma;   Neuroendocrine Tumor;   Pancreatic Neoplasms
Interventions: Drug: Everolimus 10 mg;   Drug: Octreotide Depot
16 Withdrawn Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
Conditions: Merkel Cell Carcinoma;   Islet Cell Carcinoma;   Neuroendocrine Carcinoma;   Pituitary Tumor
Interventions: Drug: antineoplaston A10;   Drug: antineoplaston AS2-1;   Procedure: alternative product therapy;   Procedure: biological therapy;   Procedure: biologically based therapies;   Procedure: cancer prevention intervention;   Procedure: complementary and alternative therapy;   Procedure: differentiation therapy
17 Completed Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis
18 Completed Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.
Conditions: Carcinoma;   Carcinoma, Renal Cell;   Neuroendocrine Tumors;   Carcinoid Tumor;   Pancreatic Islet Cell Tumors
Intervention: Other: Blood sampling by vena punction.
19 Recruiting Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery
Conditions: Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Carcinoma;   Recurrent Islet Cell Carcinoma
Interventions: Drug: temozolomide;   Drug: pazopanib hydrochloride
20 Active, not recruiting Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Neoplastic Syndrome;   Neuroendocrine Tumor
Interventions: Biological: bevacizumab;   Drug: 5-fluorouracil;   Drug: leucovorin;   Drug: oxaliplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.